D. Roblin, “Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis”, Acta Derm Venereol, vol. 95, no. 5, pp. 542–548, Feb. 2015.